A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination

A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination

Systemically vaccinated individuals against COVID-19 and influenza may continue to support viral replication and shedding in the upper airways, contributing to the spread of infections. Thus, a vaccine regimen that enhances mucosal immunity in the respiratory mucosa is needed to prevent a pandemic....

Full description

Bibliographic Details
Main Authors:	Fumi Sato-Kaneko, Shiyin Yao, Fitzgerald S. Lao, Yukiya Sako, Jasmine Jin, Nikunj M. Shukla, Howard B. Cottam, Michael Chan, Masiel M. Belsuzarri, Dennis A. Carson, Tomoko Hayashi
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Vaccines
Subjects:	intranasal pulmonary boosting regimen influenza virus infection TLR4 agonist TLR7 agonist combination adjuvant liposomal formulation
Online Access:	https://www.mdpi.com/2076-393X/10/10/1694

Similar Items

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity
by: Fumi Sato-Kaneko, et al.
Published: (2020-06-01)

Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
by: Graham Thomas, et al.
Published: (2021-07-01)

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation
by: Floriane Auderset, et al.
Published: (2019-07-01)

The Relevance of TLR8 in Viral Infections
by: Iván Martínez-Espinoza, et al.
Published: (2022-01-01)

Scratching the Surface Takes a Toll: Immune Recognition of Viral Proteins by Surface Toll-like Receptors
by: Alexis A. Hatton, et al.
Published: (2022-12-01)

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy
by: Mayuresh M. Abhyankar, et al.
Published: (2021-06-01)

Identification of potential biomarkers of vaccine inflammation in mice
by: Paul F McKay, et al.
Published: (2019-05-01)

The Effects of Polyhexamethylene Biguanide (PHMB) and TLR Agonists Alone or as Polyplex Nanoparticles against <em>Leishmania infantum</em> Promastigotes and Amastigotes
by: Pamela Martínez-Orellana, et al.
Published: (2020-11-01)

Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
by: Amani E. Khalifa, PhD, et al.
Published: (2021-01-01)

Synthesis of protein conjugates adsorbed on cationic liposomes surface
by: Despo Chatzikleanthous, et al.
Published: (2020-01-01)

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
by: Zhichen Sun, et al.
Published: (2023-09-01)

PROSPECTS OF Toll-LIKE RECEPTOR AGONISTS AND ANTAGONISTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS
by: A. A. Nikonova, et al.
Published: (2019-07-01)

Poly(Ethylene Glycol)-Poly(Lactic Acid) TLR7 Agonist as a Novel HBsAg Immune Response Stimulant
by: BRYAN GERVAIS DE LIYIS, et al.
Published: (2023-03-01)

PROSPECTS OF TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS
by: Alexandra Alexandrovna Nikonova, et al.
Published: (2019-03-01)

Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD
by: Karthik Siram, et al.
Published: (2023-12-01)

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
by: Sudeep Kumar, et al.
Published: (2019-05-01)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
by: Kamel Chettab, et al.
Published: (2023-05-01)

Therapeutic Effects of ADU-S100 as STING Agonist and CpG ODN1826 as TLR9 Agonist in CT-26 Model of Colon Carcinoma
by: Sare Hajiabadi, et al.
Published: (2023-07-01)

Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells
by: Samo Guzelj, et al.
Published: (2022-07-01)

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
by: Marcelo V. Negrao, MD, et al.
Published: (2023-03-01)

A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis
by: Chih-Yuan Chiang, et al.
Published: (2022-03-01)

Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes
by: Woo Sik Kim, et al.
Published: (2020-10-01)

REGULATION OF TLR/RLR GENE ACTIVITY AND SYNTHESIS OF CYTOKINES DURING PHORBOL MYRISTATE ACETATE (PMA)-INDUCED DIFFERENTIATION OF THP-1 MONOCYTES INTO MACROPHAGE-LIKE CELLS
by: T. M. Sokolova, et al.
Published: (2017-01-01)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
by: Ahmed I. Younes, et al.
Published: (2021-02-01)

A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod
by: Zhongkun Zhang, et al.
Published: (2021-12-01)

Impact of Selected Bacterial and Viral Toll-like Receptor Agonists on the Phenotype and Function of Camel Blood Neutrophils
by: Jamal Hussen, et al.
Published: (2023-02-01)

Synthetic and immunological studies on the OCT4 immunodominant motif antigen-based anti-cancer vaccine
by: Tingting Chen, et al.
Published: (2020-02-01)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
by: Samik Chakraborty, et al.
Published: (2023-10-01)

COMPARATIVE ANALYSIS IMMUNOTROPIC EFFECTS IN VITRO DERINAT AND SYNTHETIC TLR9 AGONIST ON RECEPTOR FUNCTION OF NEUTROPHILIC GRANULOCYTES AND MONOCYTES IN NORMAL AND INFECTIOUS PROCESS
by: T. V. Rusinova, et al.
Published: (2016-10-01)

Novel TLR7/8 agonists promote activation of HIV-1 latent reservoirs and human T and NK cells
by: Yangyang Li, et al.
Published: (2023-01-01)

In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response
by: Qin Liu, et al.
Published: (2024-04-01)

A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages
by: Iseulys Richert, et al.
Published: (2023-09-01)

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists
by: Sehwan Jeong, et al.
Published: (2021-08-01)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
by: Lingling Huang, et al.
Published: (2022-06-01)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
by: Mohammad Enamul Hoque Kayesh, et al.
Published: (2021-11-01)

Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment
by: Dehua Lu, et al.
Published: (2023-04-01)

Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV
by: Minhee Kang, et al.
Published: (2023-09-01)

Structure and compositional analysis of aluminum oxyhydroxide adsorbed pertussis vaccine
by: Jessica Duprez, et al.
Published: (2021-01-01)

A Thermosensitive Bi‐Adjuvant Hydrogel Triggers Epitope Spreading to Promote the Anti‐Tumor Efficacy of Frameshift Neoantigens
by: Yaohua Ke, et al.
Published: (2024-04-01)

The Functional Mechanisms of Toll-Like Receptor 3 and Its Implications in Digestive System Tumors
by: Bin Han, et al.
Published: (2023-11-01)